Lorvotuzumab mertansine: Phase I data

Data from 33 patients with advanced solid tumors in the dose-escalation Phase I portion of the open-label, international Phase I/II NORTH trial showed that IMGN901 plus etoposide and carboplatin led to 10 objective responses, including 6 responses in 13 evaluable SCLC patients. The disease control rate (DCR) was 72.7%. The most common grade 3/4 adverse events were myelosuppressive events. The MTD and recommended Phase II dose of IMGN901 was 112 mg/m 2 given on days 1 and 8 of a 21-day cycle. Data were presented at the Multidisciplinary Symposium in Thoracic Oncology meeting in Chicago. ...